Trending Assets
Top investors this month
Trending Assets
Top investors this month
Dividend Investors Should Consider $GILD
Gilead Sciences hasn't been performing well in the stock market for a while. The company's stock peaked in 2015 and then was in a downtrend till 2017. Since then, the stock has been trading sideways.

Looking deeper into the company, the company has a few growth drivers worth noting.

  1. Lenacapavir, a twice-a-year injectable treatment for HIV
  2. Trodelvy, a cancer drug

For Lenacapavir, that drug is currently undergoing clinical trials and could soon receive FDA approval. The reason why many are optimistic about that drug is that it provides a great alternative to daily pills.

As for Trodelvy, that drug was approved last year. According to The Motley Fool, Trodelvy could generate $5 billion in annual revenue at its peak.

Thoughts?
The Motley Fool
2 High-Yielding Stocks Trading Near Multiyear Lows | The Motley Fool
Gilead Sciences and Unilever both currently yield over 4%.

Related
Already have an account?